Seroprevalence for SARS-CoV-2 and Associated Clinical Manifestations According to Use of PrEP, TDF/FTC, and TAF/FTC (n = 750)
| % (n) . | Without PrEP n = 250 . | PrEP n = 500 . | TDF/FTC n = 409 . | TAF/FTC n = 91 . | P* . | P** . |
|---|---|---|---|---|---|---|
| Imumunoassay for IgG Antibodies for SARS-CoV-2 | .026 | .661 | ||||
| Positive | 9.2 (23) | 15.0 (75) | 14.7 (60) | 16.5 (15) | ||
| Negative | 90.8 (227) | 85.0 (425) | 85.3 (349) | 83.5 (76) | ||
| Clinical Manifestations | .058 | .527 | ||||
| Asymptomatic | 73.2 (183) | 66.4 (332) | 65.8 (269) | 69.2 (63) | ||
| Symptomatic | 26.8 (67) | 33.6 (168) | 34.2 (140) | 30.8 (28) | ||
| Fever | 14.8 (37) | 19.0 (95) | 19.0 (79) | 17.6 (16) | .154 | .703 |
| Cough | 12.4 (31) | 16.2 (81) | 16.4 (67) | 15.4 (14) | .169 | .815 |
| Dyspnea | 4.4 (11) | 7.8 (39) | 6.6 (27) | 13.2 (12) | .078 | .035 |
| Myalgias | 6.4 (16) | 13.2 (66) | 12.2 (50) | 17.6 (16) | .005 | .172 |
| Asthenia | 9.6 (24) | 12.2 (61) | 12.2 (50) | 12.1 (11) | .290 | .971 |
| Loss of appetite | 2.0 (5) | 1.4 (7) | 1.2 (5) | 2.2 (2) | .547 | .616 |
| Anosmia | 7.2 (18) | 9.6 (48) | 37.0 (9.0) | 12.1 (11) | .274 | .430 |
| Ageusia | 4.4 (11) | 6.0 (30) | 5.1 (21) | 9.9 (9) | .364 | .084 |
| Diarrhea | 4.0 (10) | 10.4 (52) | 10.5 (43) | 9.9 (9) | .003 | .860 |
| Cephalgia | 6.0 (15) | 12.0 (60) | 12.5 (51) | 9.9 (9) | .010 | .493 |
| Skin lesions | 0.8 (2) | 1.4 (7) | 1.0 (2) | 3.3 (3) | .725 | 1.117 |
| Duration of the Symptoms | .408 | .270 | ||||
| Median days (IQR) | 7.0 (4.0–14.0) | 7.0 (4.3–13.0) | 7.0 (4.3–12.5) | 10.0 (4.3–14.0) | ||
| Specific Treatment for COVID-19 | .729 | .703 | ||||
| Yes | 2.0 (5) | 2.4 (12) | 2.7 (11) | 1.1 (1) | ||
| No | 98.0 (245) | 97.6 (488) | 97.3 (398) | 98.9 (90) |
| % (n) . | Without PrEP n = 250 . | PrEP n = 500 . | TDF/FTC n = 409 . | TAF/FTC n = 91 . | P* . | P** . |
|---|---|---|---|---|---|---|
| Imumunoassay for IgG Antibodies for SARS-CoV-2 | .026 | .661 | ||||
| Positive | 9.2 (23) | 15.0 (75) | 14.7 (60) | 16.5 (15) | ||
| Negative | 90.8 (227) | 85.0 (425) | 85.3 (349) | 83.5 (76) | ||
| Clinical Manifestations | .058 | .527 | ||||
| Asymptomatic | 73.2 (183) | 66.4 (332) | 65.8 (269) | 69.2 (63) | ||
| Symptomatic | 26.8 (67) | 33.6 (168) | 34.2 (140) | 30.8 (28) | ||
| Fever | 14.8 (37) | 19.0 (95) | 19.0 (79) | 17.6 (16) | .154 | .703 |
| Cough | 12.4 (31) | 16.2 (81) | 16.4 (67) | 15.4 (14) | .169 | .815 |
| Dyspnea | 4.4 (11) | 7.8 (39) | 6.6 (27) | 13.2 (12) | .078 | .035 |
| Myalgias | 6.4 (16) | 13.2 (66) | 12.2 (50) | 17.6 (16) | .005 | .172 |
| Asthenia | 9.6 (24) | 12.2 (61) | 12.2 (50) | 12.1 (11) | .290 | .971 |
| Loss of appetite | 2.0 (5) | 1.4 (7) | 1.2 (5) | 2.2 (2) | .547 | .616 |
| Anosmia | 7.2 (18) | 9.6 (48) | 37.0 (9.0) | 12.1 (11) | .274 | .430 |
| Ageusia | 4.4 (11) | 6.0 (30) | 5.1 (21) | 9.9 (9) | .364 | .084 |
| Diarrhea | 4.0 (10) | 10.4 (52) | 10.5 (43) | 9.9 (9) | .003 | .860 |
| Cephalgia | 6.0 (15) | 12.0 (60) | 12.5 (51) | 9.9 (9) | .010 | .493 |
| Skin lesions | 0.8 (2) | 1.4 (7) | 1.0 (2) | 3.3 (3) | .725 | 1.117 |
| Duration of the Symptoms | .408 | .270 | ||||
| Median days (IQR) | 7.0 (4.0–14.0) | 7.0 (4.3–13.0) | 7.0 (4.3–12.5) | 10.0 (4.3–14.0) | ||
| Specific Treatment for COVID-19 | .729 | .703 | ||||
| Yes | 2.0 (5) | 2.4 (12) | 2.7 (11) | 1.1 (1) | ||
| No | 98.0 (245) | 97.6 (488) | 97.3 (398) | 98.9 (90) |
Abbreviations: COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; IQR, interquartile range; PrEP, pre-exposure prophylaxis; SARS-CoV-2, severe acute respiratory sydrome coronavirus 2; TAF/FTC, tenofovir alafenamide/emtricitabine; TDF, disoproxil fumarate.
*Without PrEP vs PrEP.
**TDF/FTC vs TAF/FTC.
Seroprevalence for SARS-CoV-2 and Associated Clinical Manifestations According to Use of PrEP, TDF/FTC, and TAF/FTC (n = 750)
| % (n) . | Without PrEP n = 250 . | PrEP n = 500 . | TDF/FTC n = 409 . | TAF/FTC n = 91 . | P* . | P** . |
|---|---|---|---|---|---|---|
| Imumunoassay for IgG Antibodies for SARS-CoV-2 | .026 | .661 | ||||
| Positive | 9.2 (23) | 15.0 (75) | 14.7 (60) | 16.5 (15) | ||
| Negative | 90.8 (227) | 85.0 (425) | 85.3 (349) | 83.5 (76) | ||
| Clinical Manifestations | .058 | .527 | ||||
| Asymptomatic | 73.2 (183) | 66.4 (332) | 65.8 (269) | 69.2 (63) | ||
| Symptomatic | 26.8 (67) | 33.6 (168) | 34.2 (140) | 30.8 (28) | ||
| Fever | 14.8 (37) | 19.0 (95) | 19.0 (79) | 17.6 (16) | .154 | .703 |
| Cough | 12.4 (31) | 16.2 (81) | 16.4 (67) | 15.4 (14) | .169 | .815 |
| Dyspnea | 4.4 (11) | 7.8 (39) | 6.6 (27) | 13.2 (12) | .078 | .035 |
| Myalgias | 6.4 (16) | 13.2 (66) | 12.2 (50) | 17.6 (16) | .005 | .172 |
| Asthenia | 9.6 (24) | 12.2 (61) | 12.2 (50) | 12.1 (11) | .290 | .971 |
| Loss of appetite | 2.0 (5) | 1.4 (7) | 1.2 (5) | 2.2 (2) | .547 | .616 |
| Anosmia | 7.2 (18) | 9.6 (48) | 37.0 (9.0) | 12.1 (11) | .274 | .430 |
| Ageusia | 4.4 (11) | 6.0 (30) | 5.1 (21) | 9.9 (9) | .364 | .084 |
| Diarrhea | 4.0 (10) | 10.4 (52) | 10.5 (43) | 9.9 (9) | .003 | .860 |
| Cephalgia | 6.0 (15) | 12.0 (60) | 12.5 (51) | 9.9 (9) | .010 | .493 |
| Skin lesions | 0.8 (2) | 1.4 (7) | 1.0 (2) | 3.3 (3) | .725 | 1.117 |
| Duration of the Symptoms | .408 | .270 | ||||
| Median days (IQR) | 7.0 (4.0–14.0) | 7.0 (4.3–13.0) | 7.0 (4.3–12.5) | 10.0 (4.3–14.0) | ||
| Specific Treatment for COVID-19 | .729 | .703 | ||||
| Yes | 2.0 (5) | 2.4 (12) | 2.7 (11) | 1.1 (1) | ||
| No | 98.0 (245) | 97.6 (488) | 97.3 (398) | 98.9 (90) |
| % (n) . | Without PrEP n = 250 . | PrEP n = 500 . | TDF/FTC n = 409 . | TAF/FTC n = 91 . | P* . | P** . |
|---|---|---|---|---|---|---|
| Imumunoassay for IgG Antibodies for SARS-CoV-2 | .026 | .661 | ||||
| Positive | 9.2 (23) | 15.0 (75) | 14.7 (60) | 16.5 (15) | ||
| Negative | 90.8 (227) | 85.0 (425) | 85.3 (349) | 83.5 (76) | ||
| Clinical Manifestations | .058 | .527 | ||||
| Asymptomatic | 73.2 (183) | 66.4 (332) | 65.8 (269) | 69.2 (63) | ||
| Symptomatic | 26.8 (67) | 33.6 (168) | 34.2 (140) | 30.8 (28) | ||
| Fever | 14.8 (37) | 19.0 (95) | 19.0 (79) | 17.6 (16) | .154 | .703 |
| Cough | 12.4 (31) | 16.2 (81) | 16.4 (67) | 15.4 (14) | .169 | .815 |
| Dyspnea | 4.4 (11) | 7.8 (39) | 6.6 (27) | 13.2 (12) | .078 | .035 |
| Myalgias | 6.4 (16) | 13.2 (66) | 12.2 (50) | 17.6 (16) | .005 | .172 |
| Asthenia | 9.6 (24) | 12.2 (61) | 12.2 (50) | 12.1 (11) | .290 | .971 |
| Loss of appetite | 2.0 (5) | 1.4 (7) | 1.2 (5) | 2.2 (2) | .547 | .616 |
| Anosmia | 7.2 (18) | 9.6 (48) | 37.0 (9.0) | 12.1 (11) | .274 | .430 |
| Ageusia | 4.4 (11) | 6.0 (30) | 5.1 (21) | 9.9 (9) | .364 | .084 |
| Diarrhea | 4.0 (10) | 10.4 (52) | 10.5 (43) | 9.9 (9) | .003 | .860 |
| Cephalgia | 6.0 (15) | 12.0 (60) | 12.5 (51) | 9.9 (9) | .010 | .493 |
| Skin lesions | 0.8 (2) | 1.4 (7) | 1.0 (2) | 3.3 (3) | .725 | 1.117 |
| Duration of the Symptoms | .408 | .270 | ||||
| Median days (IQR) | 7.0 (4.0–14.0) | 7.0 (4.3–13.0) | 7.0 (4.3–12.5) | 10.0 (4.3–14.0) | ||
| Specific Treatment for COVID-19 | .729 | .703 | ||||
| Yes | 2.0 (5) | 2.4 (12) | 2.7 (11) | 1.1 (1) | ||
| No | 98.0 (245) | 97.6 (488) | 97.3 (398) | 98.9 (90) |
Abbreviations: COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; IQR, interquartile range; PrEP, pre-exposure prophylaxis; SARS-CoV-2, severe acute respiratory sydrome coronavirus 2; TAF/FTC, tenofovir alafenamide/emtricitabine; TDF, disoproxil fumarate.
*Without PrEP vs PrEP.
**TDF/FTC vs TAF/FTC.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
